RT Journal Article
SR Electronic
T1 “PLEXIT - Therapeutic plasma exchange (TPE) for Covid-19 cytokine release storm (CRS), a retrospective propensity matched control study”
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.23.20160796
DO 10.1101/2020.07.23.20160796
A1 Kamran, Sultan Mehmood
A1 Mirza, Zill-e-Humayun
A1 Naseem, Arshad
A1 Liaqat, Jahanzeb
A1 Fazal, Imran
A1 Alamgir, Wasim
A1 Saeed, Farrukh
A1 Azam, Rizwan
A1 Hussain, Maryam
A1 Yousaf, Muhammad Ali
A1 Ashraf, Nadeem
A1 Nisar, Shazia
A1 Zafar Ali, Muhammad
A1 Saleem, Salman
A1 Sajjad, Kaswar
A1 Zaman, Asad
A1 Azam, Malik Nadeem
A1 Hussain, Mehmood
A1 Iftikhar, Raheel
YR 2020
UL http://medrxiv.org/content/early/2020/07/29/2020.07.23.20160796.abstract
AB Purpose To evaluate the outcome of patients with COVID-19 triggered CRS treated with Therapeutic Plasma Exchange (TPE) as compared to propensity score matched (PSM)-controls not receiving TPE.Material and methods Using PS 1:1 matching, 90 patients were assigned 2 groups (45 receiving TPE and 45 controls). Forced matching and covariate matching was done to overcome bias between two groups.Results Median age was 60 years (range 32-73 in TPE and 37-75 in non-TPE group), p= 0.325. Median duration of symptoms 7 days (range 3-22 days in TPE and 3-20 days in non-TPE), p=0.266. Disease severity in both groups was 6.6% moderate, 44.4% severe and 49% critical. Twenty-eight-day survival was significantly superior in TPE group (91.1%) as compared to PS-matched controls (61.5%), HR 0.21, 95% CI for HR 0.09-0.53, log rank 0.002. Median duration of hospitalization was significantly reduced in TPE treated group as compared to non-TPE controls 10 days and 15 days respectively (p< 0.01). CRS resolution time was also significantly reduced in TPE treated group (6 days vs. 12 days) (p< 0.001).Conclusion Use of TPE is associated with superior overall survival, early resolution of CRS and time to discharge as compared to standard therapy for COVID-19 triggered CRS.Highlights□ Cytokine release syndrome (CRS) plays a pivotal role in pathophysiology and progression to severe and critical disease in patients with COVID-19.□ Beyond supportive care, there are currently no proven effective treatment options (including Tocilizumab) for coronavirus disease (COVID-19)□ Therapeutic plasma exchange (TPE) may dampen CRS of COVID-19 by removing circulating cytokines and toxins□ TPE is the cheapest of all novel treatments available so far to treat severe to critical COVID-19□ By intervening early with TPE, mortality and morbidity associated with COVID-19 triggered CRS can be reducedCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04485169Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Review Committee Pak Emirates Military Hospital RawalpindiAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available and can be shared on reasonable demand via email